...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Key Players
Reply New Message
Prev Message Back To Forum Threaded View Next Message

I'm not sure if there was a question there. But I do agree that since we are near cycle 4, based upon being 12 weeks from date of first dosing, this likely indicates that DLTs were not encountered in the beginning phases/cycle. A Zenith quarterly update or AGM would clear this up quick. In the meantime.........

4 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply